Lao PDR Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Lao PDR
2. Grant number: 17-LAO-12c-X / /
3. Date of Decision Letter: December 16, 2016
4. Date of the Partnership Framework Agreement: June 7, 2013
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine
6. Vaccine type: Pneumococcal
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th></th>
<th>2013-2016</th>
<th>2017</th>
<th>Total²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget</td>
<td>7,166,790³</td>
<td>1,186,000</td>
<td>8,352,790</td>
</tr>
</tbody>
</table>

10. Vaccine introduction grant (in US$): Not applicable

11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement)⁴

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2013-2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Pneumococcal vaccines doses</td>
<td></td>
<td>314,700</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>7,166,790⁵</td>
<td>1,186,000</td>
</tr>
</tbody>
</table>

¹ This is the entire duration of the Programme.
² This is the total amount endorsed by Gavi for the entire duration of the Programme.
³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
⁴ This is the amount that Gavi has approved.
⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
12. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. **Self-procurement:** Not applicable

14. **Co-financing obligations:** Reference code: 17-LAO-12c-X-C
   
   According to the co-financing policy, the Country falls within the group Accelerated transition.

   The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>34,900</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>35,800</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td></td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>400</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>115,070</td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>122,500</td>
</tr>
</tbody>
</table>

15. **Operational support for campaigns:** Not applicable

16. **Additional reporting requirements:** Not applicable

   Reports and other information | Due dates
   -----------------------------|-----------
   To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | May
   In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Secretariat

17. **Financial clarifications:** Not applicable

18. **Other conditions:** Not applicable

Signed by,

On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
December 16, 2016